UK Devices Agency faces 3% cost reduction:
This article was originally published in Clinica
Among the UK Medical Device Agency's key business targets for 1995/96 is a 3% reduction in running costs while maintaining levels of activity. The MDA should also aim to recover 65% of the costs of the Manufacturer's Registration Scheme (compared with a 40% goal in 1994/5) and to release at least 20% of the evaluation programme funds for the NHS. Other targets include improving value for money provided by the evaluation centres by extending the scope of the services provided, handling smoothly the imminent relocation of offices and improving the handling of customer communications.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.